Related references
Note: Only part of the references are listed.Behind the Numbers: Decoding Molecular Phenotypes with Radiogenomics-Guiding Principles and Technical Considerations
Michael D. Kuo et al.
RADIOLOGY (2014)
Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation
Neema Jamshidi et al.
RADIOLOGY (2014)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes
Hyun-Ju Lee et al.
RADIOLOGY (2013)
Radiogenomic Analysis of Breast Cancer Using MRI: A Preliminary Study to Define the Landscape
Shota Yamamoto et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2012)
Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non-Small-Cell Lung Cancer
Eva E. Schaake et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Non-Small Cell Lung Cancer: Identifying Prognostic Imaging Biomarkers by Leveraging Public Gene Expression Microarray Data-Methods and Preliminary Results
Olivier Gevaert et al.
RADIOLOGY (2012)
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
D. R. Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Mari Mino-Kenudson et al.
CLINICAL CANCER RESEARCH (2010)
Feature Selection with the Boruta Package
Miron B. Kursa et al.
JOURNAL OF STATISTICAL SOFTWARE (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
Maximilian Diehn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma
Michael D. Kuo et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2007)
Decoding global gene expression programs in liver cancer by noninvasive imaging
Eran Segal et al.
NATURE BIOTECHNOLOGY (2007)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications
T Kosaka et al.
CANCER RESEARCH (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
JW Park et al.
CLINICAL CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The new World Health Organization classification of lung tumours
E Brambilla et al.
EUROPEAN RESPIRATORY JOURNAL (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
